Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader...
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical...
CHATHAM, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced...
Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company working to accelerate the development...
15 of 18 patients remain alive of those recruited since the study reopened in 2021.Longer than expected patient survival data...
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data...
Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates...
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™...
FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first...
Providence, RI, April 13, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic Migraine Trials by Eliminating Interim Analyses Topline Results Expected for Both Programs...
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12,...
CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology...
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Preliminary revenue to be within the range of $7.3 - $7.8 million and expected to be the strongest first-quarter results...
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin...